Современное место эхинокандинов в терапии и профилактике инвазивных микозов: краткий обзор | КМАХ

Современное место эхинокандинов в терапии и профилактике инвазивных микозов: краткий обзор

Клиническая микробиология и антимикробная химиотерапия. 2020; 22(3):197-209

​ Веселов А.В.
10.36488/cmac.2020.3.197-209
эхинокандины антимикотики Candida кандидоз аспергиллез инвазивные грибковые инфекции
Раздел
Антимикробные препараты
Тип
Обзор
Публикация
Клиническая микробиология и антимикробная химиотерапия. 2020; 22(3):197-209

Аннотация

Инвазивные грибковые инфекции продолжают демонстрировать неуклонный рост в различных популяциях пациентов, сопровождаясь высокими показателями как заболеваемости, так и атрибутивной летальности. Для терапии инвазивных микозов в настоящее время доступно небольшое число препаратов, к которым относятся полиены, азолы, эхинокандины, аллиламины и флуцитозин. Среди указанных групп эхинокандины – анидулафунгин, каспофунгин и микафунгин – представляют собой ключевой класс противогрибковых препаратов, прежде всего для терапии самой распространенной формы системных грибковых инфекций – инвазивного кандидоза. Обладая уникальным механизмом действия, обуславливающим фунгицидную активность в отношении дрожжевых патогенов, предсказуемым профилем фармакокинетики, а также хорошей переносимостью, эхинокандины прочно заняли лидирующие позиции в терапии инфекций, вызванных грибами рода Candida. Помимо этого, они используются в терапии рефрактерных случаев инвазивного аспергиллеза и для профилактики инвазивных микозов в отдельных популяциях пациентов. В данном обзоре приведены основные клинико-фармакологические характеристики эхинокандинов, а также представлено их позиционирование в текущих версиях практических рекомендаций.

Веселов Александр Валерьевич

НИИ антимикробной химиотерапии ФГБОУ ВО СГМУ Минздрава России, Смоленск, Россия

  • 1. Brown G.D., Denning D.W., Gow N.A., Levitz S.M., Netea M.G., White T.C. Hidden killers: human fungal infections. Sci Transl Med. 2012;4:165rv13. DOI: 10.1126/scitranslmed.3004404
  • 2. Sanguinetti M., Posteraro, B., Lass-Flörl C. Antifungal drug resistance among Candida species: Mechanisms and clinical impact. Mycoses. 2015;58:2-13. DOI: 10.1111/myc.12330
  • 3. Klimko N., Kozlova Y., Khostelidi S., Shadrivova O., Borzova Y., Burygina E., et al. The burden of serious fungal diseases in Russia. Mycoses. 2015;58(Suppl. 5):58-62. DOI: 10.1111/myc.12388
  • 4. Bassetti M., Bouza E. Invasive mould infections in the ICU setting: complexities and solutions. J Antimicrob Chemother. 2017;(72 Suppl. 1):i39-i47. DOI: 10.1093/jac/dkx032
  • 5. Perlin D.S. Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci. 2015;1354:1-11. DOI: 10.1111/nyas.12831
  • 6. Stan C.D., Tuchiluş C., Stan C.I. Echinocandins – new antifungal agents. Rev Med Chir Soc Med Nat Iasi. 2014;118(2):528-536. PMID: 25076727
  • 7. Odds F.C., Brown A.J., Gow N.A. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11:272-279. DOI: 10.1016/s0966-842x(03)00117-3
  • 8. Aguilar-Zapata D., Petraitiene R., Petraitis V. Echinocandins: the expanding antifungal armamentarium. Clin Infect Dis. 2015;61:S604-S611. DOI: 10.1093/cid/civ814
  • 9. Balkovec J.M., Hughes D.L., Masurekar P.S., Sable C.A., Schwartz R.E., Singh S.B. Discovery and development of first in class antifungal caspofungin (CANCIDAS®) – A case study. Nat Prod Rep. 2014;31:15-34. DOI: 10.1039/c3np70070d
  • 10. U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of MYCAMINE® (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age; Astellas Pharma US, Inc.: Tokyo, Japan. Available at: www.astellas.com/us/news/4761 (Accessed June 14, 2020).
  • 11. Cappelletty D., Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy. 2007;27:369-388. DOI: 10.1592/phco.27.3.369
  • 12. Sucher A.J., Chahine E.B., Balcer H.E. Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009;43:1647-1657. DOI: 10.1345/aph.1M237
  • 13. Chowdhary A., Sharma C., Meis J.F. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017;13:e1006290. DOI: 10.1371/journal.ppat.1006290
  • 14. Chowdhary A., Voss A., Meis J.F. Multidrug-resistant Candida auris: ‘new kid on the block’ in hospital-associated infections? J Hosp Infect. 2016;94:209-212. DOI: 10.1016/j.jhin.2016.08.004
  • 15. European Committee on Antimicrobial Susceptibility Testing Clinical Breakpoints for Antifungals. Available at: www.eucast.org/astoffungi/clinicalbreakpointsforantifungals/ (Accessed June 13, 2020).
  • 16. Espinel-Ingroff A., Arendrup M.C., Pfaller M.A., Bonfietti L.X., Bustamante B., Canton E., et al. Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother. 2013;57(12):5836-5842. DOI: 10.1128/AAC.01519-13
  • 17. Nivoix Y., Ledoux M.P., Herbrecht R. Antifungal therapy: new and evolving therapies. Semin Respir Crit Care Med. 2020;41(1):158174. DOI: 10.1055/s-0039-3400291
  • 18. Walker L.A., Gow N.A., Munro C.A. Fungal echinocandin resistance. Fungal Genet Biol. 2010;47:117-126. DOI: 10.1016/j.fgb.2009.09.00
  • 19. McBride J.A., Gauthier G.M., Klein B.S. Clinical manifestations and treatment of blastomycosis. Clin Chest Med. 2017;38:435449. DOI: 10.1016/j.ccm.2017.04.006
  • 20. Thompson G.R. 3rd, Barker B.M., Wiederhold N.P. Large-scale evaluation of in vitro amphotericin B, triazole, and echinocandin activity against Coccidioides species from U.S. institutions. Antimicrob Agents Chemother. 2017;61:e02634-16. DOI: 10.1128/AAC.02634-16
  • 21. Kahn J.N., Hsu M.J., Racine F., Giacobbe R., Motyl M. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture. Antimicrob Agents Chemother. 2006;50(6):2214-2216. DOI: 10.1128/AAC.01610-05
  • 22. Park S., Kelly R., Kahn J.N., Robles J., Hsu M.-J., Register E., et al. Specific substitutions in the echinocandin target fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother. 2005;49:32643273. DOI: 10.1128/AAC.49.8.3264-3273.2005
  • 23. Grossman N.T., Chiller T.M., Lockhart S.R. Epidemiology of echinocandin resistance in Candida. Curr Fungal Infect Rep. 2014;8:243-248. DOI: 10.1007/s12281-014-0209-7
  • 24. Castanheira M., Woosley L.N., Diekema D.J., Messer S.A., Jones R.N., Pfaller M.A. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother. 2010;54:2655-2659. DOI: 10.1128/AAC.01711-09
  • 25. Alexander B.D., Johnson M.D., Pfeiffer C.D., Jiménez-Ortigosa C., Catania J., Booker R., et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of fks mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56:1724-1732. DOI: 10.1093/cid/cit136
  • 26. Coste A.T., Kritikos A., Li J., Khanna N., Goldenberger D., Garzoni C., et al. Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland. Infection. 2020. Online ahead of print. DOI: 10.1007/s15010-020-01475-8
  • 27. Veselov A.V., Vasilyeva N.V., Bogomolova T.S., Raush E.R., Kutsevalova O.Yu., Nizhegorodtseva I.A., et al. Susceptibility testing of Candida glabrata clinical strains to echinocandins using SensititreTM YeastOneTM system. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2018;20(1):49-54. Russian. (Веселов А.В., Васильева Н.В., Богомолова Т.С., Рауш Е.Р., Куцевалова О.Ю., Нижегородцева И.А. и соавт. Определение чувствительности клинических штаммов Candida glabrata к эхинокандинам с помощью системы Sensititre™ YeastOne™. Клиническая микробиология и антимикробная химиотерапия. 2018;20(1):49-54.) DOI: 10.36488/cmac.2018.1.49-54
  • 28. Centers for Disease Control and Prevention. Infection Prevention and Control for Candida auris. Available at: www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html (Accessed July 9, 2020).
  • 29. Schelenz S., Hagen F., Rhodes J.L., Abdolrasouli A., Chowdhary A., Hall A., et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5:35. DOI: 10.1186/s13756-016-0132-5
  • 30. Calvo B., Melo A.S., Perozo-Mena A., Hernandez M., Francisco E.C., Hagen F., et al. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Infect. 2016;73:369-374. DOI: 10.1016/j.jinf.2016.07.008
  • 31. Sears D., Schwartz B.S. Candida auris: an emerging multidrugresistant pathogen. Int J Infect Dis. 2017;63:95-98. DOI: 10.1016/j.ijid.2017.08.017
  • 32. Al Maani A., Paul H., Al-Rashdi A., Al Wahaibi A., Al-Jardani A., Al Abri A.M., et al. Ongoing challenges with healthcareassociated Candida auris outbreaks in Oman. J Fungi (Basel). 2019;5:101. DOI: 10.3390/jof5040101
  • 33. Chowdhary A., Prakash A., Sharma C., Kordalewska M., Kumar A., Sarma S., et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (200917) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018;73:891899. DOI: 10.1093/jac/dkx480
  • 34. Ruggero M.A., Topal J.E. Development of echinocandin-resistant Candida albicans candidemia following brief prophylactic exposure to micafungin therapy. Transpl Infect Dis. 2014;16:469472. DOI: 10.1111/tid.12230
  • 35. Bizerra F.C., Jimenez-Ortigosa C., Souza A.C., Breda G.L., Queiroz-Telles F., Perlin D.S., et al. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin. Antimicrob Agents Chemother. 2014;58:2438-2440. DOI: 10.1128/AAC.02189-13
  • 36. Fekkar A., Dannaoui E., Meyer I., Imbert S., Brossas J.Y., Uzunov M., et al. Emergence of echinocandin-resistant Candida spp. in a hospital setting: A consequence of 10 years of increasing use of antifungal therapy? Eur J Clin Microbiol Infect Dis. 2014;33:14891496. DOI: 10.1007/s10096-014-2096-9
  • 37. Shields R.K., Nguyen M.H., Clancy C.J. Clinical perspectives on echinocandin resistance among Candida species. Curr Opin Infect Dis. 2015;28:514-522. DOI: 10.1097/QCO.0000000000000215
  • 38. Perlin D.S. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs. 2014;74:1573-1585. DOI: 10.1007/s40265-014-0286-5
  • 39. Shields R.K., Nguyen M.H., Press E.G., Cumbie R., Driscoll E., Pasculle A.W., et al. Rate of FKS mutations among consecutive Candida isolates causing bloodstream infection. Antimicrob Agents Chemother. 2015;59:7465-7470. DOI: 10.1128/AAC.01973-15
  • 40. Niimi K., Maki K., Ikeda F., Holmes A.R., Lamping E., Niimi M., et al. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob Agents Chemother. 2006;50:11481155. DOI: 10.1128/AAC.50.4.1148-1155.2006
  • 41. Perlin D.S. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007;10:121-130. DOI: 10.1016/j.drup.2007.04.002
  • 42. Lesage G., Bussey H. Cell wall assembly in Saccharomyces cerevisiae. Microbiol Mol Biol Rev. 2006;70:317-343. DOI: 10.1128/MMBR.00038-05
  • 43. Cowen L.E., Steinbach W.J. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell. 2008;7:747-764. DOI: 10.1128/EC.00041-08
  • 44. Felton T., Troke P.F., Hope W. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;1:68-88. DOI: 10.1128/CMR.00046-13
  • 45. Eschenauer G., Depestel D., Carveret P., et al. Comparison of echinocandin antifungals. Ther Clin Risk Manag. 2007;1:71-97. DOI: 10.2147/tcrm.2007.3.1.71
  • 46. Perlin D.S. Current perspectives on echinocandin class drugs. Future Microbiol. 2011;6:441-457. DOI: 10.2217/fmb.11.19
  • 47. Kartsonis N.A., Nielsen J., Douglas C.M. Caspofungin: The first in a new class of antifungal agents. Drug Resist Updat. 2003;6:197-218. DOI: 10.1016/s1368-7646(03)00064-5
  • 48. Vazquez J.A. Anidulafungin: a new echinocandin with a novel profile. Clin Ther. 2005;27(6):657-673. DOI: 10.1016/j.clinthera.2005.06.010
  • 49. Patil A., Majumdar S. Echinocandins in antifungal pharmacotherapy. J Pharm Pharmacol. 2017;69(12):1635-1660. DOI: 10.1111/jphp.12780
  • 50. Wiederhold N.P., Lewis J.S. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007;8:1155-1166. DOI: 10.1517/14656566.8.8.1155
  • 51. Kapralos I., Mainas E., Apostolopoulou O., Siopi M., Neroutsos E., Apostolidi S., et al. Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intra-subject variability. Br J Clin Pharmacol. 2020;10.1111/bcp.14457. DOI: 10.1111/bcp.14457
  • 52. Chen S., Slavin M., Sorrell T. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71(1):11-41. DOI: 10.2165/11585270-000000000-00000
  • 53. Villanueva A., Arathoon E., Gotuzzo E., Berman R., DiNubile M., Sable C. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis. 2001;9:1529-1535. DOI: 10.1086/323401
  • 54. Villanueva A., Gotuzzo E., Arathoon E., Noriega L.M., Kartsonis N., Lupinacci R., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002;4:294-299. DOI: 10.1016/s0002-9343(02)01191-9
  • 55. Arathoon E., Gotuzzo E., Noriega L.M., Berman R., DiNubile M., Sable C. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother. 2002;2:451-457. DOI: 10.1128/aac.46.2.451-457.2002
  • 56. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., ThompsonMoya L., Smietana J., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020-2029. DOI: 10.1056/NEJMoa021585
  • 57. Maertens J., Raad I., Petrikkos G., Boogaerts M., Selleslag D., Petersen F.B., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;11:15631571. DOI: 10.1086/423381
  • 58. Aoun M. Clinical efficacy of caspofungin in the treatment of invasive aspergillosis. Med Mycol. 2006;1:S363-S366. DOI: 10.1080/13693780600860961
  • 59. Colombo A., Ngai A.L., Bourque M., Bradshaw S., Strohmaier K., Taylor A., et al. Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database. Antimicrob Agents Chemother. 2010;5:1864-1871. DOI: 10.1128/AAC.0091109
  • 60. Maertens J., Egerer G., Shin W.S., Reichert D., Stek M., Chandwani S., et al. Caspofungin use indaily clinical practice for treatmentof invasive aspergillosis: results of aprospective observational registry. BMC Infect Dis. 2010;1:182. DOI: 10.1186/1471-2334-10-182
  • 61. Groll A., Attarbaschi A., Schuster F.R., Herzog N., Grigull L., Dworzak M.N., et al. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J Antimicrob Chemother. 2006;57:527-535. DOI: 10.1093/jac/dkl009
  • 62. Mattiuzzi G., Alvarado G., Giles F.J., Ostrosky-Zeichner L., Cortes J., O'brien S., et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2005;1:143-147. DOI: 10.1128/AAC.50.1.143-147.2006
  • 63. Doring M., Hartmann U., Erbacher A., Lang P., Handgretinger R., Müller I. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis. BMC Infect Dis. 2012;12:151. DOI: 10.1186/1471-2334-12-151
  • 64. Kohno S., Masaoka T., Yamaguchi H., Mori T., Urabe A., Ito A., et al. A multicenter, open label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis. 2004;5:372-379. DOI: 10.1080/00365540410020406
  • 65. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., Mullane K.M., Vazquez J., Anaissie E.J., et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis. 2005;10:654-661. DOI: 10.1007/s10096-005-0024-8
  • 66. Kuse E.-R., Chetchotisakd P., da Cunha C., Ruhnke M., Barrios C., Raghunadharao D., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369(9572):15191527. DOI: 10.1016/S0140-6736(07)60605-9
  • 67. De Wet N., Llanos-Cuentas A., Suleiman J., Baraldi E., Krantz E., Della Negra M., et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;6:842-849. DOI: 10.1086/423377
  • 68. Andes D., Reynolds D.K., Van Wart S.A., Lepak A.J., Kovanda L., Bhavnani S.M. Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization. Antimicrob Agents Chemother. 2013;11:57145716. DOI: 10.1128/AAC.01057-13
  • 69. Van Burik J., Ratanatharathorn V., Stepan D., Miller C.B., Lipton J.H., Vesole D.H., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;10:1407-1416. DOI: 10.1086/422312
  • 70. Huang X., Chen H., Han M., Zou P., Wu D., Lai Y., et al. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2012;10:1509-1516. DOI: 10.1016/j.bbmt.2012.03.014
  • 71. Arrieta A., Maddison P., Groll A.H. Safety of micafungin in pediatric clinical trials. Pediatr Infect Dis J. 2011;6:e97-e102. DOI: 10.1097/INF.0b013e3182127eaf
  • 72. Manzoni P, Wu C, Tweddle L, Roilides E. Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials. Pediatr Infect Dis J. 2014;33(11):e291-8. DOI: 10.1097/INF.0000000000000434
  • 73. Krause D., Simjee A.E., van Rensburg C., Viljoen J., Walsh T.J., Goldstein B.P., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004;6:770-775. DOI: 10.1086/423378
  • 74. Krause D., Reinhardt J., Vazquez J.A., Reboli A., Goldstein B.P., Wible M., et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004;6:2021-2024. DOI: 10.1128/AAC.48.6.20212024.2004
  • 75. Reboli A., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;24:2472-2482. DOI: 10.1056/NEJMoa066906
  • 76. Winston D., Limaye A.P., Pelletier S., Safdar N., Morris M.I., Meneses K., et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. 2014;12:2758-2764. DOI: 10.1111/ajt.12963
  • 77. Ruhnke M., Paiva J.A., Meersseman W., Pachl J., Grigoras I., Sganga G., et al. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clin Microbiol Infect. 2012;7:680-687. DOI: 10.1111/j.14690691.2012.03784.x
  • 78. Benjamin D.K. Jr, Driscoll T., Seibel N.L., Gonzalez C.E., Roden M., Kilaru R., et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006;2:632-638. DOI: 10.1128/AAC.50.2.632-638.2006
  • 79. Roilides E., Carlesse F., Tawadrous M., Leister-Tebbe H., Conte U., Raber S., et al. Safety, efficacy and pharmacokinetics of anidulafungin in patients 1 month to <2 years of age with invasive candidiasis, including candidemia. Pediatr Infect Dis J. 2020;39:305-309. DOI: 10.1097/INF.0000000000002568
  • 80. Roilides E., Carlesse F., Leister-Tebbe H., Conte U., Yan J.L., Liu P., et al. A prospective, open-label study to assess the safety, tolerability and efficacy of anidulafungin in the treatment of invasive candidiasis in children 2 to <18 years of age. Pediatr Infect Dis J. 2019;38:275-279. DOI: 10.1097/INF.0000000000002237
  • 81. Klimko N.N., Rubinchik V.Ye., Sobol M.M., Larionova V.B., Tyrenko V.V., Talipova L.I., et al. Multicenter observational study of anidulafungin using – ERA (Eraxis in Russia). Problemy medicinskoj mikologii. 2018;20(3):21-25. Russian. (Климко Н.Н., Рубинчик В.Е., Соболь М.М., Ларионова В.Б., Тыренко В.В., Талипова Л.И. и соавт. Результаты проспективного многоцентрового исследования применения анидулафунгина – ЭРА (Эраксис в Российской Федерации). Проблемы медицинской микологии. 2018;20(3):21-25.)
  • 82. Pappas P.G., Kauffman C.A., Andes D.R., Clancy C.J., Marr K.A., Ostrosky-Zeichner L., et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50. DOI: 10.1093/cid/civ933
  • 83. Ullmann A., Aguado J.M., Arikan-Akdagli S., Denning D.W., Groll A.H., Lagrou K., et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMIDECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl. 1):e1-e38. DOI: 10.1016/j.cmi.2018.01.002
  • 84. Tissot F., Agrawal S., Pagano L., Petrikkos G., Groll A.H., SkiadaA., et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433444. DOI: 10.3324/haematol.2016.152900
  • 85. Maertens J.A., Girmenia C., Brüggemann R.J., Duarte R.F., Kibbler C., Ljungman P., et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221-3230. DOI: 10.1093/jac/dky286
  • 86. Ruhnke M., Cornely O., Schmidt-Hieber M., Alakel N., Boell B., Buchheidt D., et al. Treatment of invasive fungal diseases in cancer patients-revised 2019 recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Mycoses. 2020;63(7):653682. DOI: 10.1111/myc.13082
  • 87. Capoor M.R., Subudhi C.P., Collier A., Bal A.M. Antifungal stewardship with an emphasis on candidaemia. J Glob Antimicrob Resist. 2019;19:262-268. DOI: 10.1016/j.jgar.2019.05.030
  • 88. Ioannidis K., Papachristos A., Skarlatinis I., Kiospe F., Sotiriou S., Papadogeorgaki E., et al. Do we need to adopt antifungal stewardship programmes? Eur J Hosp Pharm. 2020;27(1):14-18. DOI: 10.1136/ejhpharm-2017-001467
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились